Genetic Testing & Personalized Medicine
•32 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (32)
| Company | Market Cap | Price |
|---|---|---|
|
ZTS
Zoetis Inc.
Zoetis engages in genetic testing and personalized medicine for animal health, fitting Genetic Testing & Personalized Medicine.
|
$64.15B |
$144.07
+0.33%
|
|
NTRA
Natera, Inc.
The company provides genetic testing panels (Panorama NIPT, Horizon Carrier Screening, Signatera cfDNA testing) and personalized medicine data.
|
$27.16B |
$198.94
+2.96%
|
|
LH
Labcorp Holdings Inc.
Labcorp expanded genetic testing capabilities (e.g., Invitae integration) and offers genetic testing and personalized medicine services.
|
$21.10B |
$253.95
+0.64%
|
|
TEM
Tempus AI, Inc.
Genetic Testing & Personalized Medicine – Tempus provides genetic testing services (Ambry) and hereditary screening, aligning with precision medicine.
|
$15.55B |
$89.85
+4.15%
|
|
COO
The Cooper Companies, Inc.
Reproductive genetic testing and embryo analysis initiatives place COO in Genetic Testing & Personalized Medicine.
|
$13.95B |
$69.92
-0.27%
|
|
EXAS
Exact Sciences Corporation
The company’s core products (Oncotype DX, Oncodetect, etc.) and pipeline support Genetic Testing & Personalized Medicine as a primary growth driver.
|
$12.20B |
$64.69
+2.33%
|
|
WGS
GeneDx Holdings Corp.
Core business: genetic testing and personalized medicine using exome/genome sequencing and interpretation.
|
$3.93B |
$136.83
+4.05%
|
|
VCYT
Veracyte, Inc.
Tests are genetic/genomic classifiers used to guide personalized cancer treatment decisions.
|
$2.83B |
$36.10
+2.19%
|
|
ADPT
Adaptive Biotechnologies Corporation
Genetic Testing & Personalized Medicine tag applies to ADPT's immune genomics and diagnostic data assets.
|
$2.64B |
$17.36
+2.69%
|
|
AZTA
Azenta, Inc.
Genetic sequencing and personalized genomics services fit Genetic Testing & Personalized Medicine.
|
$1.38B |
$30.21
+1.05%
|
|
NEOG
Neogen Corporation
Neogen's genomics services and bovine-focused genomics capabilities align with Genetic Testing & Personalized Medicine.
|
$1.34B |
$6.17
+2.75%
|
|
PSNL
Personalis, Inc.
Company provides genetic testing and personalized medicine through sequencing-based diagnostics and biomarker analysis.
|
$851.45M |
$9.61
+1.05%
|
|
CDNA
CareDx, Inc
Engages in Genetic Testing & Personalized Medicine via gene expression testing and cfDNA analyses relevant to transplant diagnostics.
|
$835.21M |
$15.02
+3.80%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Genetic Testing & Personalized Medicine aligns with sequencing and diagnostic data generation.
|
$760.33M |
$12.99
+8.16%
|
|
MYGN
Myriad Genetics, Inc.
Direct genetic testing and personalized medicine focus; core Myriad offerings include MyRisk, HRD, Prolaris, Prequel, etc.
|
$741.11M |
$8.04
+1.07%
|
|
FLGT
Fulgent Genetics, Inc.
Core genetic testing and personalized medicine platform.
|
$683.46M |
$22.44
-0.62%
|
|
LAB
Standard BioTools Inc.
Genomics and personalized medicine capabilities supported by the multi-omics platform.
|
$455.79M |
$1.20
+4.35%
|
|
SOPH
SOPHiA GENETICS S.A.
Genetic Testing & Personalized Medicine: platform supports genetic/genomic testing and tailored therapeutic insights.
|
$332.19M |
$4.95
-4.62%
|
|
PRE
Prenetics Global Limited
CircleDNA consumer genetic tests utilize genetic testing and personalized medicine capabilities.
|
$181.14M |
$14.76
+4.31%
|
|
NAUT
Nautilus Biotechnology, Inc.
Nautilus' proteomics capability supports genetic testing and personalized medicine research contexts.
|
$167.99M |
$1.33
-5.32%
|
|
LUCD
Lucid Diagnostics Inc.
EsoGuard analyzes DNA methylation biomarkers (VIM, CCNA1), placing it in the genetic testing and personalized medicine category.
|
$130.91M |
$1.20
|
|
BDSX
Biodesix, Inc.
Genetic testing and molecular profiling are core to IQLung ddPCR/NGS and biomarker-based testing.
|
$50.05M |
$6.98
+6.24%
|
|
VNRX
VolitionRx Limited
Epigenetic biomarker profiling aligns with Genetic Testing & Personalized Medicine as a diagnostic service.
|
$44.71M |
$0.43
-1.68%
|
|
ACUT
Accustem Sciences Inc.
Company's core products are genomic diagnostic tests (MSC Lung Test and StemPrintER) targeting cancer, aligning with Genetic Testing & Personalized Medicine.
|
$19.45M |
$1.21
|
|
PRPH
ProPhase Labs, Inc.
Nebula Genomics whole-genome sequencing and the DNA Expand platform provide genetic testing and personalized medicine offerings.
|
$15.11M |
$0.36
-1.51%
|
|
MDXH
MDxHealth S.A.
GPS is a genomic profiling test reflecting personalized medicine approaches in cancer diagnostics.
|
$13.43M |
$4.92
+0.72%
|
|
LUDG
Ludwig Enterprises, Inc.
Uses buccal cell-based genetic/molecular testing for personalized medicine.
|
$11.38M |
$0.07
|
|
BGLC
BioNexus Gene Lab Corp.
MRNA Scientific's RNA-based blood tests align with Genetic Testing & Personalized Medicine.
|
$9.74M |
$5.38
+3.66%
|
|
CDIO
Cardio Diagnostics Holdings, Inc.
Core product: genetic testing and personalized medicine for cardiovascular risk assessment.
|
$7.02M |
$4.40
+5.01%
|
|
DQWS
DSwiss, Inc.
B2B DNA genotyping private-label services fall under genetic testing & personalized medicine.
|
$6.62M |
$0.03
|
|
IDXG
Interpace Biosciences, Inc.
Offers genetic testing and personalized medicine services through sequencing and analysis of genomic material for cancer diagnostics.
|
$4.12M |
$1.02
|
|
MYNZ
Mainz Biomed B.V.
Mainz Biomed’s flagship ColoAlert and PancAlert are genetic biomarker-based tests used for non-invasive cancer detection and stratification, aligning with Genetic Testing & Personalized Medicine.
|
$946703 |
$1.48
-1.67%
|
Loading company comparison...
Loading industry trends...
Loading research report...
